Paul Hastings Advised J.P. Morgan as Sole Book-Running Manager in Secondary Offering by Certain Stockholders of Harmony Biosciences
Paul Hastings LLP advised J.P. Morgan as the sole book-running manager in connection with the secondary offering by certain selling stockholders of Harmony Biosciences Holdings, Inc. The offering is expected to close on November 1, 2024, subject to customary closing conditions.
Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi and partner Will Magioncalda led the Paul Hastings team, which also included associates Jessica Kelly and Adam Swank.
More details can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.